Dhanbad News Paper

Hyperuricemia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Hyperuricemia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

September 28
18:25 2020
Hyperuricemia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Hyperuricemia – Market Insights, Epidemiology, and Market Forecast-2030”

(Albany, US) DelveInsight has launched a new report on “Hyperuricemia – Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s Hyperuricemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the facts

  • The most recent significant study of hyperuricemia and gout found that 43.3 million Americans have the condition.
  • The prevalence rate of hyperuricemia in the general population is estimated at 20-25%, but only 4-6% in premenopausal women
  • The prevalence of gout is 5.9% in men and 2% in women.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hyperuricemia-market

 

Scope of the Report

  • The report covers the descriptive overview of Hyperuricemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hyperuricemia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hyperuricemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hyperuricemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hyperuricemia market

 

Hyperuricemia occurs when there’s too much uric acid in your blood. High uric acid levels can lead to several diseases, including a painful type of arthritis called gout. Elevated uric acid levels are also associated with health conditions such as heart disease, diabetes, and kidney disease.

Uric acid is formed when purines break down in your body. Purines are chemicals found in certain foods. This typically includes:

  • red meat
  • organ meat
  • seafood
  • beans

Normally, your body rids itself of uric acid when you urinate. Hyperuricemia occurs when your body either makes too much uric acid or is unable to excrete enough of it. It usually happens because your kidneys aren’t eliminating it quickly enough.

Excess uric acid levels in your blood can lead to the formation of crystals. Although these can form anywhere in the body, they tend to form in and around your joints and in your kidneys. Your body’s defensive white blood cells may attack the crystals, causing inflammation and pain.

Rates of hyperuricemia have risen sharply since 1960.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hyperuricemia-market

 

The major players covered in the hyperuricemia drugs market are:

  • Takeda Pharmaceutical Company Limited
  • Mylan N.V.
  • Sun Pharmaceutical Industries Limited
  • Hikma Pharmaceutical PLC
  • Dr. Reddy’s Laboratories Ltd
  • Sanofi
  • Sandoz AG
  • Amneal Pharmaceuticals LLC
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hyperuricemia-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Hyperuricemia

3. Competitive Intelligence Analysis for Hyperuricemia

4. Hyperuricemia: Market Overview at a Glance

4.1. Hyperuricemia Total Market Share (%) Distribution in 2017

4.2. Hyperuricemia Total Market Share (%) Distribution in 2030

5. Hyperuricemia: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Hyperuricemia Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Hyperuricemia Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Hyperuricemia Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Hyperuricemia Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Hyperuricemia Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Hyperuricemia Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Hyperuricemia Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Hyperuricemia Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Hyperuricemia Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Hyperuricemia Treatment and Management

8.2. Hyperuricemia Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Hyperuricemia Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Hyperuricemia: Seven Major Market Analysis

13.1. Key Findings

13.2. Hyperuricemia Market Size in 7MM

13.3. Hyperuricemia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Hyperuricemia Total Market Size in the United States

15.1.2. Hyperuricemia Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Hyperuricemia Total Market Size in Germany

15.3.2. Hyperuricemia Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Hyperuricemia Total Market Size in France

15.4.2. Hyperuricemia Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Hyperuricemia Total Market Size in Italy

15.5.2. Hyperuricemia Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Hyperuricemia Total Market Size in Spain

15.6.2. Hyperuricemia Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Hyperuricemia Total Market Size in the United Kingdom

15.7.2. Hyperuricemia Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Hyperuricemia Total Market Size in Japan

15.8.3. Hyperuricemia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hyperuricemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=Pressrelease&utm_medium=Pressrelease&utm_campaign=Pressrelease


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/dhanbadnewspaper.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share